Abstract:Identification of immunogenic targets against hepatitis B virus (HBV)-encoded proteins will provide crucial advances in developing potential antibody therapies. In this study, 63 treatment-naive patients with chronic HBV infection and 46 patients who achieved hepatitis B surface antigen loss (sAg loss) following antiviral treatment were recruited. Moreover, six patients who transitioned from the hepatitis B e antigen-positive chronic infection phase (eAg(+)CInf) to the hepatitis phase (eAg(+)CHep) were enrolled from real-life clinical practice. Additionally, telbivudine-treated eAg(+)CHep patients and relapsers or responders from an off-treatment cohort were longitudinally studied. The frequencies and function of B cells were assessed by flow cytometry. We devised a peptide array composed of 15-mer overlapping peptides of HBV-encoded surface (S), core (C), and polymerase (P) proteins and performed a screening on B-cell linear epitopes with sera. Naive B cells and plasmablasts were increased, whereas total memory, activated memory (AM), and atypical memory (AtM) B cells were reduced in sAg(-) patients compared with sAg(+) patients. Importantly, longitudinal observations found that AtM B cells were associated with successful treatment withdrawal. Interestingly, we identified six S-specific dominant epitopes (S33, S34, S45, S76, S78, and S89) and one C-specific dominant epitope (C37) that reacted with the majority of sera from sAg(-) patients. Of note, more B-cell linear epitopes were detected in CHep patients with alanine aminotransferase (ALT) flares than in nonflare CInf patients, and five B-cell linear epitopes (S4, S5, S10, S11, and S68) were overwhelmingly recognized by ALT flare patients. The recognition rates of epitopes on C and P proteins were significantly increased in CHep patients relative to CInf patients. Strikingly, a statistically significant elevation in the number of positive epitopes was observed when ALT nonflare patients shifted into the flare phase. Moreover, S76 identified at baseline was confirmed to be associated with a complete response after 48 weeks of telbivudine therapy. Taken together, we identified several functional cure-related B-cell linear epitopes of chronic HBV infection, and these epitopes may serve as vaccine candidates to elicit neutralizing antibodies to treat HBV infection.

Screening of Anti-Hepatitis B Virus Polypeptides

Identification and Mapping of HBsAg Loss-Related B-Cell Linear Epitopes in Chronic HBV Patients by Peptide Array

Screening and Identification of HBV Epitopes Restricted by Multiple Prevalent HLA-A Allotypes.

Construction of HLA-A2-peptide tetramer and application in HBV/HCV infection]

Biopanning of HGV epitope from a phage displayed library

Establishment of a human cell line with a surface display system for screening and optimizing Na+-taurocholate cotransporting polypeptide-binding peptides

Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators

Screening of lymphocyte proteins interacting with hepatitis B virus X antigen by yeast-two hybrid technique

Screening and Identification of Interacting Proteins with Hepatitis B Virus Core Protein in Leukocytes and Cloning of New Gene C1

Screening, Expression and Characterization of a Novel Protein Binding to Hepatitis B Surface Antigen

An Aptamer Targets Hbv Core Protein And Suppresses Hbv Replication In Hepg2.2.15 Cells

Intracellular-Delivery Of A Single-Chain Antibody Against Hepatitis B Core Protein Via Cell-Penetrating Peptide Inhibits Hepatitis B Virus Replication In Vitro

HBx-Derived Constrained Peptides Inhibit the Secretion of Hepatitis B Virus Antigens

Preparation and functional evaluation of monoclonal antibodies targeting Hepatitis B Virus Polymerase

Characterization and Engineering of Broadly Reactive Monoclonal Antibody Against Hepatitis B Virus X Protein That Blocks Its Interaction with DDB1.

Construction of HMGN2 recombinant expression plasmid and its anti-βhepatitis virus activity

Artificial Recombinant Cell-Penetrating Peptides Interfere with Envelopment of Hepatitis B Virus Nucleocapsid and Viral Production.

Discovery of New Hepatitis B Virus Capsid Assembly Modulators by an Optimal High-Throughput Cell-Based Assay

Selection of HBV preS1 binding penta peptides by phage display

An E. Coli-Produced Single-Chain Variable Fragment (scfv) Targeting Hepatitis B Virus Surface Protein Potently Inhibited Virion Secretion.

Construction and expression of eukaryotic expression plasmid carrying mutant of hepatitis B virus X with C-terminal deletions